Health
China’s 2nd protein subunit COVID-19 vaccine to enter clinical trials, easy to mass produce – Global Times
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed…
Sinopharm’s COVID-19 vaccine. Photo: VCG
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed recombinant subunit vaccine candidate into clinical trials.
Sinopharm’s vaccine is the second protein subunit vaccine in the country after one developed by China’s Anhui Zhifei Longcom Biopharmaceutical Co, which started late-stage trials in Pakistan upon approval on Sunday.
The protein subunit vaccine…
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News11 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
General24 hours agoLiberals dump NSW candidate who said women should not serve in ADF combat